Advancements in Virus-Like Particle-Mediated Cytosine Base Editing Show Promising In Vivo Efficacy
Virus-like particles (VLPs) have long been heralded as a promising vehicle for delivering genome editors with high precision. However, their application for cytosine base editing (CBE) in living organisms has faced significant obstacles, primarily due to low editing efficiencies. Recent research now unveils a critical bottleneck in this process—insufficient inhibition of uracil DNA glycosylases (UDGs)—which degrade edited sites and limit the durability of CBE efficiency.
A team led by Zhu et al. addressed this challenge by engineering a novel cytosine base editor termed transformer base editor (tBE), which was optimized to robustly inhibit UDG activity within cells. This improved mechanism safeguards the uracil intermediates generated during C-to-T conversion, thus enhancing editing persistence and effectiveness. The tBE was subsequently packaged into VLPs to facilitate precise in vivo delivery.
In their rigorous animal models, tBE-VLPs demonstrated remarkable editing efficiencies. A single systemic injection in mice led to average editing rates of 46.0% at the mouse Pcsk9 locus and 64.2% at the Hpd locus within the liver. Furthermore, targeted delivery to the retinal pigment epithelium achieved an average 24.2% editing at the Vegfa gene, underscoring the platform’s versatility across diverse tissue types.
These editing rates translated to meaningful therapeutic outcomes in mouse disease models. Pcsk9 editing is known to reduce cholesterol levels, while Hpd editing can alleviate symptoms of hereditary tyrosinemia. Vegfa editing in the eye is associated with modulating vascular growth, relevant to diseases such as age-related macular degeneration. The study confirmed that tBE-VLP treatment produced beneficial physiological effects aligned with gene correction.
A key advantage of this approach is its superior specificity. Off-target editing events were undetectable both in vitro and in vivo, addressing a major concern associated with base editor delivery methods. Comparison with adeno-associated virus (AAV) vectors and lipid nanoparticle (LNP) mRNA delivery highlighted the enhanced precision of tBE-VLPs, underscoring their safety profile for potential translational applications.
Mechanistically, the enhancement comes from the improved recruitment of uracil DNA glycosylase inhibitor proteins within the tBE editing complex. By preventing excision of uracil bases, the tBE maintains base conversions until DNA replication or repair solidifies the desired C-to-T substitutions. This insight into enzymatic inhibition marks a critical step forward for base editing technology.
Beyond demonstrating robust editing in challenging tissues like the retina and liver, the study’s findings open avenues for broadening the therapeutic landscape of base editing. The modularity of VLPs combined with the refined inhibitor design promises scalable, transient, and safe genome editing interventions without viral genome integration risks.
Zhu and colleagues’ work represents a milestone in genome engineering, establishing transformer base editor VLPs as an efficient and accurate in vivo cytosine base editing system. As the field advances, this platform may catalyze novel treatments for genetic diseases with precision previously unachievable using traditional delivery methods.
With exciting potential for human therapeutic development, tBE-VLPs stand poised to revolutionize the future of gene editing by marrying efficacy, specificity, and safety in a virus-inspired delivery system.
Subject of Research: In vivo cytosine base editing with virus-like particles and uracil DNA glycosylase inhibition
Article Title: Efficient in vivo cytosine base editing using virus-like particles with uracil DNA glycosylase inhibition
Article References:
Zhu, J., Ding, L., Liu, KM. et al. Efficient in vivo cytosine base editing using virus-like particles with uracil DNA glycosylase inhibition. Nat Biotechnol (2026). https://doi.org/10.1038/s41587-026-03227-9
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41587-026-03227-9
Tags: gene editing for disease treatmenthigh-efficiency base editing in animal modelsin vivo genome editingliver-specific gene editingoptimization of base editors for in vivo useretinal pigment epithelium genome modificationsystemic delivery of genome editorstissue-specific delivery of cytosine base editorstransformer base editor developmenturacil DNA glycosylase inhibitionVirus-like particle-mediated cytosine base editingVLP-based gene therapy
